Allergan plc (AGN) Key Developments | Reuters.com
Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

230.55USD
29 Jun 2016
Change (% chg)

$2.83 (+1.24%)
Prev Close
$227.72
Open
$230.80
Day's High
$234.55
Day's Low
$227.72
Volume
4,380,062
Avg. Vol
4,692,408
52-wk High
$340.34
52-wk Low
$195.50

Latest Key Developments (Source: Significant Developments)

Allergan's botox wins Japanese approval to treat crow's feet lines
Monday, 23 May 2016 04:30pm EDT 

Allergan Plc : Allergan's botox vista® (botulinum toxin type a) receives national marketing authorisation in japan for treatment of crow's feet lines in adult patients .Japanese ministry of health, labour and welfare has approved an additional use for botox vista as a treatment for crow's feet lines.  Full Article

Allergan CEO says company is "weeks away" from closing Teva deal
Monday, 23 May 2016 11:59am EDT 

Allergan CEO : Allergan CEO says company is free to do multibillion dollar deals after Teva transaction closes .CEO Saunders says the company is "weeks away" from closing its asset sale to Teva Pharmaceuticals Full Article

Valeant Pharmaceuticals provides update regarding regulatory matters
Monday, 16 May 2016 08:24pm EDT 

Valeant Pharmaceuticals International Inc : Expects to make Canadian required filings on or before June 10, 2016. . Advised by Autorité des marchés financiers that management cease trade order will be dated and published on May 17 , 2016 .Valeant Pharmaceuticals provides update regarding regulatory matters.  Full Article

Valeant Pharmaceuticals provides update regarding regulatory matters
Monday, 16 May 2016 07:00pm EDT 

Valeant Pharmaceuticals International Inc : Expects to make Canadian required filings on or before June 10, 2016. . Advised by Autorité des marchés financiers that management cease trade order will be dated and published on May 17 , 2016 .Valeant Pharmaceuticals provides update regarding regulatory matters.  Full Article

Allergan announces positive pivotal trial results for Oculeve Intranasal Tear Neurostimulator
Monday, 16 May 2016 07:22am EDT 

Allergan Plc : Allergan announces positive pivotal trial results for oculeve intranasal tear neurostimulator . Two pivotal trials of oculeve intranasal tear neurostimulator met primary, secondary endpoints . Fda submission on-track for second half of 2016 .All device-related adverse events were mild in nature; there were no device-related serious adverse events.  Full Article

Allergan Q1 loss per share $0.38 from continuing operations
Tuesday, 10 May 2016 07:52am EDT 

Allergan : Company reiterates 2016 continuing operations guidance . Company reiterates 2016 continuing operations guidance . Namenda XR revenues in Q1 of 2016 were $173 million , as prescriptions,formulary coverage remained stable following loss of exclusivity of Namenda IR . Amortization expense for Q1 2016 was $1.6 billion , compared to $788 million in Q1 of 2015 . GAAP diluted EPS to $3.04 . Q1 non-GAAP earnings per share $3.04 from continuing operations . Q1 gaap loss per share $0.38 from continuing operations . Q1 earnings per share view $3.01 -- Thomson Reuters I/B/E/S .Q1 revenue $3.8 billion versus I/B/E/S view $3.95 billion.  Full Article

Allergan announces share repurchase program of up to $10 bln
Tuesday, 10 May 2016 07:26am EDT 

Allergan Plc : Company expects to execute $4 - $5 billion in open market repurchases . If favorable market conditions persist, will consider extending program following completion of initial portion of share repurchase program . Share repurchase program is pending completion of and receipt of proceeds from divestiture of Allergan's global generics business to Teva . Will have ability to pay down debt to maintain co's investment grade credit ratings through capital deployment after Teva deal closes .Allergan announces board authorization for share repurchase program of up to $10 billion.  Full Article

Teva still expects 4 pct U.S. generic price erosion
Monday, 9 May 2016 08:30am EDT 

: Teva Pharm says still expects 4 percent price erosion for its U.S. generic drugs in 2016 . Teva Pharm says still expects cost synergies, tax savings of $1.4 billion annually from Actavis deal Further company coverage: [TEVA.TA] (Reporting by Tova Cohen) ((tova.cohen@thomsonreuters.com;)).  Full Article

Valeant says expects to file quarterly report by June 10
Monday, 9 May 2016 08:00am EDT 

Valeant Pharmaceuticals Announces Expected Timing Of Form 10 : Expects to file its form 10-Q for quarter ended march 31, 2016 on or before June 10, 2016 . Expects quarterly filings for quarter ending June 30, 2016 and thereafter will be filed with SEC and Canadian regulators on timely basis .Valeant Pharmaceuticals announces expected timing of form 10-Q filing and reiterates 2016 first quarter guidance.  Full Article

Allergan plc receives FDA approval and launches first generic version of CRESTOR
Monday, 2 May 2016 07:30am EDT 

Allergan plc:Says has received final approval from FDA on its abbreviated new drug application for rosuvastatin calcium 5, 10, 20 and 40 mg tablets.  Full Article

Photo

Impax buys generic drugs from Teva, Allergan for $586 million

Impax Laboratories Inc said it would buy a portfolio of generic drugs from Teva Pharmaceutical Industries Ltd and Allergan Plc for about $586 million.